All the presymptomatic babies have had appropriate psychomotor development by acquiring the skills expected of healthy peers in an appropriate time frame, independently of the type of therapy administered; the two symptomatic newborns with 2 SMN2 copies also responded well to the therapy, achieving much better psychomotor development than would be naturally expected for severe SMA forms. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.